CGAS and non-small cell lung carcinoma: Recently, we also established that cGAS-STING activation in peripheral blood mononuclear cells (PBMCs) from lung cancer patients, particularly those with NSCLC, may serve as a novel predictive biomarker for response to immunotherapy [9].